Abstract:Severe asthma is a complex and heterogeneous clinical condition presented as chronic inflammation of the airways. Conventional treatments are mainly focused on symptom control; however, there has been a shift towards personalized medicine. Identification of different phenotypes driven by complex pathobiological mechanisms (endotypes), especially those driven by type-2 (T2) inflammation, has led to improved treatment outcomes. Combining biomarkers with T2-targeting monoclonal antibodies is crucial for developing personalized treatment strategies. Several biological agents, including anti-immunoglobulin E, anti-interleukin-5, and anti-thymic stromal lymphopoietin/interleukin-4, have been approved for the treatment of severe asthma. These biological therapies have demonstrated efficacy in reducing asthma exacerbations, lowering eosinophil count, improving lung function, diminishing oral corticosteroid use, and improving the quality of life in selected patients. Severe asthma management is undergoing a profound transformation with the introduction of ongoing and future biological therapies. The availability of novel treatment options has facilitated the adoption of phenotype/endotype-specific approaches and disappearance of generic interventions. The transition towards precision medicine plays a crucial role in meticulously addressing the individual traits of asthma pathobiology. An era of tailored strategies has emerged, allowing for the successful targeting of immune-inflammatory responses that underlie uncontrolled T2-high asthma. These personalized approaches hold great promise for improving the overall efficacy and outcomes in the management of severe asthma. This article comprehensively reviews currently available biological agents and biomarkers for treating severe asthma. With the expanding repertoire of therapeutic options, it is becoming increasingly crucial to comprehend the influencing factors, understand the pathogenesis, and track treatment progress in severe asthma.

Evolving phenotypes to endotypes: is precision medicine achievable in asthma?

The understanding of asthma pathogenesis in the era of precision medicine

Classification of Pediatric Asthma: From Phenotype Discovery to Clinical Practice

Different endotypes and phenotypes drive the heterogeneity in severe asthma

Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease

Choosing the right biologic treatment for individual patients with severe asthma - lessons learnt from Picasso

Biologics in Asthma: A Molecular Perspective to Precision Medicine

Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases

Immunologic aspects of asthma: from molecular mechanisms to disease pathophysiology and clinical translation

Personalized asthma management in pediatric patients based on treatment response

Precision care in the treatment of pediatric asthma

Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease

Asthma in the Precision Medicine Era: Biologics and Probiotics

Biologic Medications for Severe Asthma: Implications for Understanding Pathogenic Heterogeneity and Endotypes

Approaches to studying the pathogenesis of asthma

From Biomarkers to Biologics

Phenotyping of Severe Asthma in the Era of Broad-acting Anti-asthma Biologics

Pharmacogenetic and pharmacogenomic considerations of asthma treatment

Lung function, airway and peripheral basophils and eosinophils are associated with molecular pharmacogenomic endotypes of steroid response in severe asthma

Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?